Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
Top Cited Papers
- 10 June 2011
- journal article
- clinical trial
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (7), 673-680
- https://doi.org/10.1016/s1470-2045(11)70124-3
Abstract
No abstract availableKeywords
Funding Information
- the French Ministry of Health (PHRC #P782)
This publication has 34 references indexed in Scilit:
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Antiangiogenic agents and late anastomotic complicationsJournal of Surgical Oncology, 2010
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- From Theoretical Synergy to Clinical Supra-Additive ToxicityJournal of Clinical Oncology, 2009
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958